- Trials with a EudraCT protocol (365)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
365 result(s) found for: Thyroid diseases.
Displaying page 1 of 19.
| EudraCT Number: 2012-004295-19 | Sponsor Protocol Number: 1209-EnTF | Start Date*: 2014-10-08 | |||||||||||||||||||||
| Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||||||||||||
| Full Title: A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line t... | |||||||||||||||||||||||
| Medical condition: Histologically confirmed differentiated or medullary thyroid cancer by local pathologist. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BE (Completed) IT (Completed) GB (Completed) NL (Completed) DK (Completed) FR (Completed) ES (Completed) PL (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2013-000422-58 | Sponsor Protocol Number: D4203C00011 | Start Date*: 2013-07-02 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™) 300 mg in Patients with Papillary or Poorly Differentiated T... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Papillary Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: CZ (Completed) SE (Completed) IT (Completed) ES (Completed) DK (Completed) FR (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-003668-11 | Sponsor Protocol Number: E7080-G000-604 | Start Date*: 2018-07-30 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Eisai Ltd. | ||||||||||||||||||||||||||||||||||||||
| Full Title: An open-label, multi-center, roll-over study to assess long term safety of lenvatinib monotherapy or lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: solid tumors or lymphomas, as defined in parent protocol | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) NL (Completed) ES (Prematurely Ended) BE (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2018-001066-42 | Sponsor Protocol Number: GETNE-T1812 | Start Date*: 2020-02-20 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Spanish Group of Neuroendocrine Tumors (GETNE) | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma - The DUTHY trial | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC). Advanced medullary thyroid carcino... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-005366-17 | Sponsor Protocol Number: 2020/ABM/01/00100 | Start Date*: 2022-09-14 | |||||||||||
| Sponsor Name:Medical University of Bialystok | |||||||||||||
| Full Title: Evaluation of METtformin effect on the fertility of patients treated with 131I for THYRoid cancer – METHYR Study. | |||||||||||||
| Medical condition: Thyroid papilare cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: PL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-023428-26 | Sponsor Protocol Number: D4200C00088 | Start Date*: 2011-01-31 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medu... | |||||||||||||
| Medical condition: Locally advanced or metastatic medullary thyroid cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) IT (Completed) AT (Completed) GB (Completed) SE (Completed) FI (Completed) GR (Ongoing) DK (Completed) PL (Completed) NO (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-002269-47 | Sponsor Protocol Number: STH18441 | Start Date*: 2015-12-02 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||||||||||||||||||||||||||||||||||||||
| Full Title: Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Iodine-refractory thyroid cancer of papillary, follicular, Hürthle cell or poorly differentiated carcinoma | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2012-003814-15 | Sponsor Protocol Number: 2012-784 | Start Date*: 2013-03-06 | |||||||||||
| Sponsor Name:HOSPICES CIVILS DE LYON | |||||||||||||
| Full Title: A multicenter phase II pilot open label study to evaluate the efficacy and safety of BKM120 in the treatment of patients with advanced or metastatic differentiated thyroid cancers | |||||||||||||
| Medical condition: Follicular or poorly differentiated cancer refractory to radio iodine | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-003579-21 | Sponsor Protocol Number: RAI2012 | Start Date*: 2012-09-25 | |||||||||||
| Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO | |||||||||||||
| Full Title: Effect of the withdrawal of anti-thyroid treatment on the iodide 123 kynetics used for the dosmetry before radioiodine therapy with 131I for autoimmune hyperthyroidism. | |||||||||||||
| Medical condition: Autoimmune hyperthyroidism (Graves-Basedow disease) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000742-21 | Sponsor Protocol Number: 2017/2527 | Start Date*: 2017-07-31 | |||||||||||||||||||||
| Sponsor Name:Gustave Roussy | |||||||||||||||||||||||
| Full Title: Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with... | |||||||||||||||||||||||
| Medical condition: Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients with RAS or BRAF mutation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2022-002419-48 | Sponsor Protocol Number: GETNE-T2216 | Start Date*: 2023-03-27 | |||||||||||||||||||||
| Sponsor Name:Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE) | |||||||||||||||||||||||
| Full Title: Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. | |||||||||||||||||||||||
| Medical condition: Patients with radioiodine-refractory differentiated thyroid cancer (DTC). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2017-004570-34 | Sponsor Protocol Number: 01045-ATLEP | Start Date*: 2018-11-15 | ||||||||||||||||
| Sponsor Name:Medical Center - University of Freiburg | ||||||||||||||||||
| Full Title: Phase II, Open-label, Study in Patients with anaplastic (ATC) or poorly differentiated thyroid carcinomas (PDTC) to investigate the Clinical Efficacy and Safety of the Combination Therapy of Lenvat... | ||||||||||||||||||
| Medical condition: Anaplastic (ATC) or Poorly Differentiated Thyroid Carcinoma (PDTC) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2007-005933-12 | Sponsor Protocol Number: E7080-G000-201 | Start Date*: 2009-10-29 | |||||||||||
| Sponsor Name:Eisai Limited | |||||||||||||
| Full Title: Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified... | |||||||||||||
| Medical condition: Medullary thyroid cancer [MTC] or radioiodine (131*I) refractory/resistant differentiated thyroid cancer[DTC]: Determine the pharmacokinetic (PK) profile and the pharmacokinetic/pharmacodynamic (PK... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) PL (Completed) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-005017-71 | Sponsor Protocol Number: CHOCOLATE | Start Date*: 2016-04-02 | |||||||||||
| Sponsor Name:Centre François Baclesse | |||||||||||||
| Full Title: Diagnostic value of 18F-choline PET in patients with indeterminate cytology thyroid nodule : A pilot study | |||||||||||||
| Medical condition: Patient with a thyroid nodule ≥15mm with indefinite cytology according to the 2008 Bethesda classification (vesicular lesion of undetermined significance; follicular neoplasm or cell Hürthle; lesi... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-005077-29 | Sponsor Protocol Number: D4200C00058 | Start Date*: 2006-11-23 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Adva... | |||||||||||||
| Medical condition: Medullary thyroid cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) NL (Completed) FR (Completed) BE (Completed) HU (Completed) PT (Completed) SE (Ongoing) DK (Completed) AT (Completed) IT (Completed) GB (Completed) CZ (Completed) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-024133-23 | Sponsor Protocol Number: NO25530 | Start Date*: 2011-10-31 | |||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
| Full Title: An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor RO5185426 in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) positive for the BRAF V600 Mutation and Resista... | |||||||||||||
| Medical condition: Metastatic or unresectable papillary thyroid cancer positive for BRAFV600 mutation and resistant to radioactive iodine therapy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-001024-31 | Sponsor Protocol Number: 08/S0501/31 | Start Date*: 2008-08-27 | |||||||||||
| Sponsor Name:University of Oxford | |||||||||||||
| Full Title: A randomised controlled trial of iodide supplementation in preterm infants with follow-up at 2 years | |||||||||||||
| Medical condition: Transient hyothyroxinaemia | |||||||||||||
|
|||||||||||||
| Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-004535-12 | Sponsor Protocol Number: KO-TIP-001 | Start Date*: 2016-02-25 | |||||||||||||||||||||
| Sponsor Name:Kura Oncology, Inc. | |||||||||||||||||||||||
| Full Title: An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations | |||||||||||||||||||||||
| Medical condition: Advanced Non-Hematological Malignancies with HRAS mutations | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2021-003524-32 | Sponsor Protocol Number: NEPHENTE | Start Date*: 2023-01-11 | |||||||||||
| Sponsor Name:Istituti Clinici Scientifici Maugeri SpA Società Benefit | |||||||||||||
| Full Title: Neoadjuvant pembrolizumab in high-risk thyroid cancers (NEPENTHE) | |||||||||||||
| Medical condition: High-risk thyroid cancers | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-001386-41 | Sponsor Protocol Number: 124-I-MN-10-02 | Start Date*: 2011-06-15 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
| Full Title: Role of PET/CT with 124I for dosimetry of thyroid carcinoma before radioisotopic treatment | |||||||||||||
| Medical condition: thyroid carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
